КОМБИНИРОВАННАЯ ТЕРАПИЯ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ: В ФОКУСЕ - ФИКСИРОВАННАЯ КОМБИНАЦИЯ АНТАГОНИСТА КАЛЬЦИЯ И ИНГИБИТОРА АПФ

1. Collins R., Peto R., McMahon S. et al. Blood pressure, stroke, and coronary heart disease. -Lancet, 1990; 335: 827-838.

2. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI)//Arch. Intern Med., 1997; 157: 2413-2446.

3. Chobanian A. N., Bakris G. L., Black H. R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report//JAMA, 2003; 289: 2560-2571. 1999

4. World Health Organization -International Society of Hypertension. Guidelines for the management of Hypertension//Hypertension, 1999; 17: 151-183. 2003

5. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension//J. Hypertension, 2003; 21: 1011-1153.

6. Dahlnf В., Sever P. S., Poulter N. R. etal. Prevention of cardiovascular events with an Antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofiuazide as required, in Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA): amulticentre randomized controlled trial//Lancet, 2005; 366: 895-906.

7. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial//Lancet, 1998, 351 (9118): 1755-1762.

8. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)//JAMA, 2000; 283: 1967-1975.

9. Pepine C.J., Handberg-Thurmond E. et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): An internet-based randomized trial in coronary artery disease patients with hypertension//JACC, 1998; 32 (5): 1228-1237.

10. Dahlof В., Devereux R. В., Kjeldsen et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol//Lancet, 2002; 359: 995-1003.

11. Opie L.H. Combination drug therapy for hypertension//Philadelphia-New York, 1997.

12. Сидоренко Б.А., Преображенский Д.В. Комбинированная терапия гипертонической болезни//Кардиология, 1997, №4, с. 18-22.

13. Комбинированная терапия больных артериальной гипертонией. Методическое письмо. Составители: И.Е.Чазова, С.А.Бойцов, ОД.Остроумова//М., 2004.

14. Psaty В., Smith N. L., Siscovick D. S. et al Health outcomes associated with antihypertensive therapies used as first-line agents. An systematic review and meta-analysis//JAMA, 1997; 277: 739-745.

15. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regims on major cardiovascular events: results of prospectively-designed overviews of randomized trials//Lancet, 2003; 362: 1527-1535.

16. Opie L.H. Clinical use of calcium channel antagonist drugs. 2th edition//Boston, 1990.

17. Epstein M. (ed.). Calcium antagonists in clinical medicine. 2nd edition//Philadelphia, 1998.

18. Сидоренко Б.А., Преображенский Д.В. Антагонисты кальция//М., 1997.

19. Сидоренко Б.А., Преображенский Д.В. Применение антагонистов кальция в кардиологической практике. -М., 1997.

20. Staessen J.A., Fagard R., Thijis L. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension//Lancet, 1997; 350: 757-564.

21. Liu L., Wang J. L., Gong L. et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension//J. Hypertension, 1998; 16: 1823-1829.

22. Meredith P.A. Role of through to peak efficacy in the evaluation of antihypertensive efficacy//J. Hypertension, 1998; 16 (suppl. 1): S59-S66.

23. Zannad E., Matzinger A., Larche J. Through/peak rations of once daily angiotensin converting enzyme inhibitors and calcium antagonists//Amer. J. Hypertension, 1996; 9 (7): 633-643.

24. Neaton J.D., Grimm R.H., Prineas R.J. et al. Treatment of Mild Hypertension Study: final results//JAMA, 1993; 270: 713-724.

25. Nissen S., Tuzcu E., Libby P. et al. Effects of antihypertensive drugs on cardiovascular events in patients with coronary heart disease and normal blood pressure. Randomized controlled CAMELOT study//JAMA, 2004; 292 (18): 2217-2226.

26. Sever P. S., Dahkrf В., Poultier N. R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): multicentre randomised controlled trial//Lancet, 2003;361: 1149-1158.

27. Sever P.S., Dahkrf В., Poultier N. R. et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.//Europ. Heart J., 2006; 27: 2982-2988.

28. Opie L.H. Angiotensin Converting Enzyme Inhibitors. 3th edition. -New York, 1999.

29. Сидоренко Б. А., Преображенский Д. В. Ингибиторы ангиотензин-превращающего фермента//Москва, 1998.

30. Сидоренко Б. А., Преображенский Д. В., Батыралиев Т. А. Ингибиторы ангиотензинпревращающего фермента. 2-е издание//Москва, 2007.

31. Архипов В. Сочетание антагонистов кальция и ингибимторов АПФ у больных артериальной гипертенезией//Врач, 2007; 8: 62-64.

32. Остроумова О.Д., Шапошник И.И., Пауков С.В. и др. Комбинированная терапия артериальной гипертонии: что нового?//РМЖ, 2007; 20: 1-6.